Compare Globus Medical Inc. Class A Common Stock (GMED) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs JPMorgan Ultra Short Income ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while JPMorgan Ultra Short Income ETF trades at $50.29 (market cap $42.48B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 4.1× Globus Medical Inc. Class A Common Stock's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and JPMorgan Ultra Short Income ETF for 47 Days on average.
| GMED | JPST | |
|---|---|---|
Market Cap | $10.25B | $42.48B |
Volume | 1,108,124 | 7,443,811 |
Sector | Health | Fixed Income |
52-Week High | $96.82 | $50.78 |
52-Week Low | $58.33 | $50.22 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.31 with minimal daily movement, reflecting its ultra-short bond strategy focused on capital preservation. The technical picture shows bearish momentum with RSI indicators mixed, while fundamental data remains limited for this income-focused ETF. Recent news highlights institutional positioning changes and ongoing investor interest in ultrashort bond strategies amid rate uncertainty.
JPST offers investors exposure to high-quality, short-duration bonds with regular dividend distributions. The fund faces competition from similar ultrashort ETFs and sensitivity to Federal Reserve policy changes. Current market conditions favor cash-alternative strategies, though expense ratios and active management performance remain key considerations for investors seeking yield with minimal risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
